Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech To Acquire AC Immune’s Beta-Amyloid Antibodies For Alzheimer’s Research

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech will pay more than $300 million for preclinical conformation-specific antibodies against beta-amyloid.

You may also be interested in...

AC Immune Seeks Partner For First Anti-Tau Vaccine To Reach The Clinic

The Swiss biotech raises $22 million in a Series D from its existing private investors to support its research into Alzheimer’s disease therapies.

Deals of the Week: Sanofi/Joslin; Merck/Ambrx; Genentech/AC Immune; GSK/Liquidia; Roche/Seaside

Walgreens’ deal to acquire Alliance Boots vastly expands its international presence but got a chilly reception on Wall Street.

NTB Measure Gains Ground In Alzheimer's

Investigator in Elan, Lilly and Myriad trials tells “The Pink Sheet” DAILY he is generally optimistic.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts